TKIs-话题@MedSci

#TKIs#

15篇内容 | 829人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2201002, encodeId=bacb2201002b8, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a> <a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a> <a href='/topic/show?id=0431113955bf' target=_blank style='color:#2F92EE;'>#SCLCs#</a>, objectTitle=首个EGFR突变小细胞肺癌临床研究！一线TKI靶药+化疗效果如何？, objectType=article, longId=823706, objectId=ab82823e06e6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=ab82823e06e6, replyNumber=0, likeNumber=93, createdTime=2024-04-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab82823e06e6, moduleTitle=首个EGFR突变小细胞肺癌临床研究！一线TKI靶药+化疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab82823e06e6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200611, encodeId=096b22006119a, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=JTO重磅：肺癌EGFR少见突变最全新整理，一二三代EGFR-TKI如何选择, objectType=article, longId=823395, objectId=daea823395ee, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, objectUrl=/article/show_article.do?id=daea823395ee, replyNumber=0, likeNumber=149, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=daea823395ee, moduleTitle=JTO重磅：肺癌EGFR少见突变最全新整理，一二三代EGFR-TKI如何选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daea823395ee)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1795743, encodeId=e6d61e9574300, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, objectType=article, longId=220637, objectId=011e22063e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011e22063e38, replyNumber=0, likeNumber=136, createdTime=2022-08-03, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011e22063e38, moduleTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=011e22063e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795742, encodeId=ca6d1e95742b5, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=89, createdTime=2022-05-02, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795745, encodeId=6ab51e9574524, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=100, createdTime=2022-06-17, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795747, encodeId=52af1e9574768, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=130, createdTime=2022-03-02, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795748, encodeId=9a2c1e95748c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=120, createdTime=2022-05-24, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795746, encodeId=412d1e95746c6, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, objectType=article, longId=294112, objectId=1b49294112ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b49294112ae, replyNumber=0, likeNumber=146, createdTime=2022-09-09, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b49294112ae, moduleTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b49294112ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795744, encodeId=60c61e957447e, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=77, createdTime=2022-06-18, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795741, encodeId=a4201e9574117, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=EGFR-TKIs药物相关口腔炎病例报告, objectType=article, longId=195842, objectId=3250195842c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3250195842c6, replyNumber=0, likeNumber=81, createdTime=2021-04-02, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3250195842c6, moduleTitle=EGFR-TKIs药物相关口腔炎病例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3250195842c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795739, encodeId=68e11e9573900, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, objectType=article, longId=183104, objectId=0beb18310413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0beb18310413, replyNumber=0, likeNumber=84, createdTime=2020-05-24, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0beb18310413, moduleTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beb18310413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795740, encodeId=18ae1e957406e, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, objectType=article, longId=185036, objectId=79b218503619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79b218503619, replyNumber=0, likeNumber=119, createdTime=2020-02-08, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79b218503619, moduleTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79b218503619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795738, encodeId=33a21e95738bb, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, objectType=article, longId=150184, objectId=a0d515018464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d515018464, replyNumber=0, likeNumber=83, createdTime=2019-01-28, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d515018464, moduleTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d515018464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795737, encodeId=b2581e95737c0, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, objectType=article, longId=134084, objectId=2a11134084c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a11134084c4, replyNumber=0, likeNumber=111, createdTime=2019-03-17, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a11134084c4, moduleTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a11134084c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795736, encodeId=91281e9573677, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, objectType=article, longId=114074, objectId=7e4c1140e4f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c1140e4f6, replyNumber=0, likeNumber=125, createdTime=2018-08-25, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c1140e4f6, moduleTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c1140e4f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795735, encodeId=c3eb1e95735a6, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, objectType=article, longId=74549, objectId=8dbde45490d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbde45490d, replyNumber=0, likeNumber=136, createdTime=2017-01-11, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbde45490d, moduleTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbde45490d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795734, encodeId=b6011e9573439, content=<a href='/topic/show?id=2f311e504f6' target=_blank style='color:#2F92EE;'>#TKIs#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=126, createdTime=2015-06-12, rootId=0, userName=yhj-time, userId=37d0457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKIs

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#小细胞肺癌# #TKIs# #SCLCs#

首个EGFR突变小细胞肺癌临床研究！一线TKI靶药+化疗效果如何？

2024-04-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #EGFR# #TKIs#

JTO重磅：肺癌EGFR少见突变最全新整理，一二三代EGFR-TKI如何选择

2024-04-26发表于上海

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察

2022-08-03

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2022-05-02

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2022-06-17

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-03-02

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-05-24

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效

2022-09-09

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2022-06-18

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

EGFR-TKIs药物相关口腔炎病例报告

2021-04-02

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

2020-05-24

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义

2020-02-08

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索

2019-01-28

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效

2019-03-17

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？

2018-08-25

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加

2017-01-11

yhj-time (审核中...)

前往app查看评论内容

#TKIs#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2015-06-12

科室
- - 订阅+
  - 更多科室
工具
服务